Ikaria, Inc, a biotherapeutics company, has appointed Craig Tooman as senior vice president (SVP) and chief financial officer (CFO). In this role, Tooman will be responsible for all financial functions of the company, as well as for information technology services. He succeeds Elizabeth Larkin, who left the company in March to pursue other interests. He will assume his new role at the beginning of August.
Tooman has over 20 years of experience in the pharmaceutical industry, and joins Ikaria from Enzon Pharmaceuticals, where he was executive vice president of finance and CFO since 2005. Prior to joining Enzon, he served as SVP of strategic planning and corporate communications at ILEX Oncology, which was acquired by Genzyme in 2004. He also played a significant role in the 2001 merger between Pharmacia & Upjohn and Monsanto that created the Pharmacia Corporation, having served in various positions within its predecessor companies Pharmacia & Upjohn and The Upjohn Company. Tooman holds an MBA from the University of Chicago, and a BA from Kalamazoo College.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.